Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older.
• People with multiple myeloma that has come back or stopped responding to treatment, and who have already received at least 3 previous treatment regimens, including specific types of therapies (a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody treatment).
• People for whom the CAR-T cell therapy called ciltacabtagene autoleucel (Carvykti) is already available.
• People who are reasonably active and able to care for themselves, as measured by a standard medical scale (ECOG score of 0, 1, or 2).
• People with a life expectancy of at least 12 weeks.
• People whose recent blood test results (taken within the past 14 days) show that their blood counts and organ function are within acceptable ranges — including red blood cells, white blood cells, platelets, liver function, and kidney function (confirm with trial site for specific numbers).
• People of childbearing potential who have had a negative pregnancy test within 7 days before joining.
• People who are sexually active and are willing to use effective contraception before, during, and for at least 30 days after the trial treatment ends.
• People willing to sign a consent form agreeing to take part.
• People willing to provide blood and bone marrow samples for research purposes.
• People willing to return to the enrolling hospital for follow-up visits during the active monitoring phase of the study.

Who may not be able to join:

• People who have an early or pre-cancerous form of the condition (such as monoclonal gammopathy of undetermined significance or smoldering multiple myeloma) or a related condition called AL amyloidosis.
• People who have not yet recovered from significant side effects of previous treatments — with an exception for mild, stable nerve-related tingling or numbness that has been stable for at least one month.
• People who are pregnant, breastfeeding, or of childbearing potential (or able to father a child) and are not willing to use adequate contraception, as the study drug is known to carry risks of harm to an unborn child.
• People who have had major surgery within 28 days before joining.
• People with serious ongoing illnesses or conditions that, in the opinion of the study doctor, would make participation unsafe or interfere with the results.
• People with a significantly weakened immune system. Note: People living with HIV who have good control of the virus and no signs of immune system weakness may still be considered eligible (confirm with trial site).
• People with certain heart or cardiovascular conditions, including uncontrolled irregular heartbeats, a heart attack or heart procedure within the past 3 months, severe heart failure, uncontrolled high blood pressure, a history of life-threatening heart rhythm problems, or an abnormal heart electrical reading above a certain level.
• People with uncontrolled ongoing infections or any other medical condition that would make participation unsafe.
• People currently taking part in another clinical trial involving a treatment for their cancer.
• People who have received a live vaccine within 6 weeks before joining.
• People who have taken certain strong medications (known as CYP3A4/5 inhibitors or inducers) — including grapefruit or St. John's Wort — within 14 days before joining. Note: short courses may be allowed with dose adjustments (confirm with trial site).
• People with a known allergy or sensitivity to the study drugs dasatinib or quercetin.
• People currently taking blood-thinning medications at full therapeutic doses (such as warfarin, heparin, or similar).
• People currently taking antiplatelet medications (such as full-dose aspirin or clopidogrel). Note: low-dose "baby" aspirin for heart protection may be allowed (confirm with trial site).
• People who have taken quinolone antibiotics (for treatment or prevention of infection) within 10 days before joining.

Important: Always verify eligibility with the trial site directly before applying.